Concord Biotech Ltd (CONCORDBIO) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10038977,
    "name": "Concord Biotech",
    "stock_name": "Concord Biotech",
    "full_name": "Concord Biotech Ltd",
    "name_url": "stocks-analysis/concord-biotech",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,349.90",
    "chg": 9.25,
    "chgp": "0.69%",
    "dir": 1,
    "prev_price": "1,340.65",
    "mcapval": "14,169.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 543960,
    "symbol": "CONCORDBIO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE338H01029",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "1.67 lacs",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/concord-biotech-10038977-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Concord Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-ltd-is-rated-sell-3998754",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ConcordBiotechL_mojoScore_3998754.png",
        "date": "2026-05-19 10:11:09",
        "description": "Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Concord Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-ltd-is-rated-sell-3981471",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/ConcordBiotechL_mojoScore_3981471.png",
        "date": "2026-05-08 10:10:22",
        "description": "Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing."
      },
      {
        "title": "Concord Biotech Ltd Surges 7.12% to Day's High of Rs 1152.3 — Outperforms Sector by 7.02 Percentage Points",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-ltd-hits-intraday-high-with-712-surge-on-29-apr-2026-3968310",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordBiotechL_priceRelatedfactors_3968310.png",
        "date": "2026-04-29 11:16:01",
        "description": "The Sensex climbed 1.25% on 29 Apr 2026, yet Concord Biotech Ltd outpaced both the benchmark and its sector with a robust 7.12% gain, touching an intraday high of Rs 1152.3. That 7.02-percentage-point outperformance signals a distinctly stock-specific rally rather than a mere market tailwind."
      },
      {
        "title": "Concord Biotech Ltd Downgraded to Sell Amid Mixed Technicals and Weak Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-ltd-downgraded-to-sell-amid-mixed-technicals-and-weak-financials-3963780",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordBiotechL_mojoScore_3963780.png",
        "date": "2026-04-27 08:15:40",
        "description": "Concord Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell as of 24 April 2026, reflecting nuanced shifts across technical indicators and financial performance metrics. Despite persistent challenges in profitability and valuation concerns, improvements in technical trends and management efficiency have moderated the outlook, prompting a recalibration of the stock’s rating within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Concord Biotech Ltd Technical Momentum Shifts Amid Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-ltd-technical-momentum-shifts-amid-prolonged-downtrend-3963720",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordBiotechL_technicaldot_3963720.png",
        "date": "2026-04-27 08:02:53",
        "description": "Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite this slight improvement, the stock continues to face significant downward pressure, reflected in its recent price action and technical indicators."
      },
      {
        "title": "Concord Biotech Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-ltd-is-rated-sell-3962153",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordBiotechL_mojoScore_3962153.png",
        "date": "2026-04-25 10:10:25",
        "description": "Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Concord Biotech Gains 1.82% Despite Strong Sell Downgrade: 4 Key Factors Driving the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-gains-182-despite-strong-sell-downgrade-4-key-factors-driving-the-week-3952159",
        "imagepath": "",
        "date": "2026-04-18 11:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>13 Apr:</strong> Downgrade to Strong Sell rating announced</p>\n                    <p><strong>15 Apr:</strong> Technical indicators signal intensified bearish momentum</p>\n                    <p><strong>17 Apr:</strong> Stock rebounds sharply, closing at Rs.1,081.25 (+4.13%)</p>\n                    <p><strong>Weekly Summary:</strong> Stock gains 1.82% vs Sensex +2.33%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,061.90</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,081.25</..."
      },
      {
        "title": "Concord Biotech Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/concord-biotech-downgraded-to-strong-sell-amid-weak-financials-and-bearish-technicals-3945312",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/ConcordBiotechL_mojoScore_3945312.png",
        "date": "2026-04-14 08:49:32",
        "description": "Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 13 April 2026. This revision reflects deteriorating technical indicators, subdued financial trends, expensive valuation metrics, and concerns over the company’s overall quality. The downgrade comes amid a challenging market environment and disappointing recent quarterly results, signalling caution for investors."
      },
      {
        "title": "Concord Biotech Gains 3.06%: Technical Shift and Financial Challenges Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/concord-biotech-gains-306-technical-shift-and-financial-challenges-shape-the-week-3942524",
        "imagepath": "",
        "date": "2026-04-11 11:00:05",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>6 Apr:</strong> Week opens at Rs.1,030.40</p>\n                    <p><strong>7 Apr:</strong> Concord Biotech upgraded to Sell on technical improvements</p>\n                    <p><strong>8 Apr:</strong> Stock rallies 1.73% amid broader market surge</p>\n                    <p><strong>10 Apr:</strong> Week closes at Rs.1,061.90, up 3.06% for the week</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,030.40</div></div>\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.1,061.90</div><div class=\"stat..."
      }
    ],
    "total": 15,
    "sid": "10038977",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/concord-biotech-10038977"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "13-Jun-2026",
      "details": "Intimation of Schedule of Analyst / Institutional Investor meeting to be held on June 17 2026 at 10:30 AM",
      "source": "BSE"
    },
    {
      "caption": "Completion Of ANVISA Inspection Conducted By The Brazilian Health Regulatory Agency At The Limbasi API Manufacturing Facility",
      "datetime": "12-Jun-2026",
      "details": "We are pleased to announce the successful completion of an ANVISA inspection conducted by the Brazilian Health Regulatory Agency at our API manufacturing facility in Limbasi. The inspection took place from June 8 to June 12 2026 and was concluded successfully.",
      "source": "BSE"
    },
    {
      "caption": "Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval For Tofacitinib Tablets 5 Mg And 10 Mg",
      "datetime": "10-Jun-2026",
      "details": "We are pleased to inform that the Company has received approval from USFDA for its ANDA for Tofacitinib Tablets 5 mg and 10 mg.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Concord Biotech Ltd has declared <strong>1070%</strong> dividend, ex-date: 03 Sep 25",
          "dt": "2025-09-03",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Concord Biotech Ltd is Rated Sell

2026-05-19 10:11:09

Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Concord Biotech Ltd is Rated Sell

2026-05-08 10:10:22

Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Concord Biotech Ltd Surges 7.12% to Day's High of Rs 1152.3 — Outperforms Sector by 7.02 Percentage Points

2026-04-29 11:16:01

The Sensex climbed 1.25% on 29 Apr 2026, yet Concord Biotech Ltd outpaced both the benchmark and its sector with a robust 7.12% gain, touching an intraday high of Rs 1152.3. That 7.02-percentage-point outperformance signals a distinctly stock-specific rally rather than a mere market tailwind.

Concord Biotech Ltd Downgraded to Sell Amid Mixed Technicals and Weak Financials

2026-04-27 08:15:40

Concord Biotech Ltd’s investment rating has been upgraded from Strong Sell to Sell as of 24 April 2026, reflecting nuanced shifts across technical indicators and financial performance metrics. Despite persistent challenges in profitability and valuation concerns, improvements in technical trends and management efficiency have moderated the outlook, prompting a recalibration of the stock’s rating within the Pharmaceuticals & Biotechnology sector.

Concord Biotech Ltd Technical Momentum Shifts Amid Prolonged Downtrend

2026-04-27 08:02:53

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a strongly bearish stance to a mildly bearish outlook. Despite this slight improvement, the stock continues to face significant downward pressure, reflected in its recent price action and technical indicators.

Concord Biotech Ltd is Rated Sell

2026-04-25 10:10:25

Concord Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 24 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 April 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Concord Biotech Gains 1.82% Despite Strong Sell Downgrade: 4 Key Factors Driving the Week

2026-04-18 11:00:05

Key Events This Week 13 Apr: Downgrade to Strong Sell rating announced 15 Apr: Technical indicators signal intensified bearish momentum 17 Apr: Stock rebounds sharply, closing at Rs.1,081.25 (+4.13%) Weekly Summary: Stock gains 1.82% vs Sensex +2.33% Week OpenRs.1,061.90 Week CloseRs.1,081.25</...

Concord Biotech Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

2026-04-14 08:49:32

Concord Biotech Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 13 April 2026. This revision reflects deteriorating technical indicators, subdued financial trends, expensive valuation metrics, and concerns over the company’s overall quality. The downgrade comes amid a challenging market environment and disappointing recent quarterly results, signalling caution for investors.

Concord Biotech Gains 3.06%: Technical Shift and Financial Challenges Shape the Week

2026-04-11 11:00:05

Key Events This Week 6 Apr: Week opens at Rs.1,030.40 7 Apr: Concord Biotech upgraded to Sell on technical improvements 8 Apr: Stock rallies 1.73% amid broader market surge 10 Apr: Week closes at Rs.1,061.90, up 3.06% for the week Week OpenRs.1,030.40 Week CloseRs.1,061.90<div class="stat...

View All News